Coya Therapeutics, Inc. has reached a significant milestone in its clinical research efforts by announcing the full enrollment of 120 patients in its Phase 2/3 ALSTARS Trial for COYA 302, a treatment aimed at amyotrophic lateral sclerosis (ALS). This development is crucial as it positions the company to gather critical data on the efficacy and safety of its therapy, with topline results expected in early Q2 2027.
The ALSTARS Trial is designed as a randomized, multi-center, double-blind, placebo-controlled study, which is a rigorous approach to testing the treatment's effectiveness. The trial will evaluate the efficacy and safety of COYA 302, a combination of proprietary low-dose IL-2 and CTLA-4 Ig. The primary endpoint focuses on changes in disease severity over time, measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R).
Founded in Houston, Texas, Coya Therapeutics operates in the pharmaceutical preparations sector (SIC 2834) and is publicly traded on the Nasdaq under the ticker symbol COYA. The company is classified as an emerging growth company, which allows it certain regulatory advantages as it seeks to advance its product candidates through clinical development.
According to the recent SEC filing (accession number 0001193125-26-413218), Coya's ALSTARS Trial will randomize approximately 120 subjects into three groups, where they will receive either one of two specified dosing regimens of COYA 302 or a placebo. Patients completing the initial 24-week double-blind phase may then enter a 24-week blinded active-treatment extension phase, allowing for an extended observation period on the treatment's impact.
The filing emphasizes that additional participants already engaged in active screening may still enroll in the trial if deemed eligible, indicating that Coya is committed to maximizing the trial's robustness and potential insights.
The implications of this trial extend beyond Coya Therapeutics. As the pharmaceutical industry increasingly focuses on neurodegenerative diseases, the outcomes of this trial could influence future research directions and funding in ALS treatment. Companies working on similar therapies will be keenly observing the results, as they may set benchmarks for efficacy and safety in the field.
Looking ahead, the next steps for Coya Therapeutics will involve the analysis of data collected during the trial phases. The company has indicated that topline data from the double-blind treatment phase are anticipated in early Q2 2027, which will be a pivotal moment for the company and its stakeholders.
As the trial progresses, Coya Therapeutics will likely continue to update investors and the public on its findings and any further developments in its research pipeline. The industry will be watching closely, as the success of COYA 302 could represent a significant advancement in the treatment of ALS.